SCHEMBL19201004

SCHEMBL19201004

CC(C)[C@H](C)CCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8557939 1.00
SCHEMBL10953408 0.91 NFKB1 (0.41)
SCHEMBL22872687 0.91 NFKB1 (0.41)
SCHEMBL22267421 0.88 DNM1 (0.44)
SCHEMBL20467587 0.88 DNM1 (0.44)
SCHEMBL28437674 0.88 NFKB1 (0.35)
SCHEMBL830074 0.87 NFKB1 (0.40)
Ammonia Solution, Strong SCHEMBL23581245 0.84 NFKB1 (0.38)
SCHEMBL31333176 0.81 GABRR1 (0.36)
SCHEMBL16297584 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11253717-B2 Aesthetic method of biological structure treatment by magnetic field BTL HEALTHCARE TECHNOLOGIES A.S. (CZ) 2022-02-22 US disclosed
WO-2021026185-A1 INDOLE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2021-02-11 WO disclosed
WO-2020081840-A1 METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS Magenta Therapeutics Inc. (US) 2020-04-23 WO disclosed
EP-3508530-A1 THERMOPLASTIC RESIN COMPOSITION, AND LAMINATE USING SAME Riken Technos Corporation (JP) 2019-07-10 EP disclosed
US-10259846-B2 Bouvardin derivatives and therapeutic uses thereof THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2019-04-16 US disclosed
US-20170342082-A1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES Bayer Pharma AG (DE) 2017-11-30 US disclosed
US-20170218025-A1 BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF SUVICA, INC. 2017-08-03 US disclosed